ImmuNext

ImmuNext is a biotechnology startup founded in 2011, focusing on the development of innovative compounds in the field of immunotherapy for cancer and autoimmune diseases. The company's slogan "ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases." emphasizes their commitment to pioneering immunotherapy solutions. ImmuNext is dedicated to the development of immune-based therapeutics for various immune-related disorders, including autoimmunity, cancer, transplantation rejection, and infectious diseases. Their approach involves targeting critical immunomodulatory molecules to restore immune homeostasis and cure diseases. ImmuNext has several significant assets in their portfolio, including an Immunometabolic Checkpoint Target, Anti-VISTA for cancer treatment, VISTA agonists for autoimmune diseases, and re-engineered Anti-CD40L antagonists for autoimmunity and graft rejection. These assets represent the company's focus on leveraging antibody-based therapeutics to target newly identified molecules, showing potential for disease remission. ImmuNext has also engaged in strategic partnerships with renowned companies such as Eli Lilly, Johnson and Johnson subsidiary - Janssen Biotech, Hoffman-La Roche, and Sanofi to advance their research and development efforts. ImmuNext's core competencies lie in discovery, target biology, and pre-clinical drug development, positioning them as a significant player in the biotechnology industry. With a robust portfolio and strategic collaborations, ImmuNext is well-positioned to make significant contributions to the advancement of immunotherapy. For more information about ImmuNext and their portfolio, interested parties can visit their website: http://immunext.com/portfolio/ and explore career opportunities at: http://immunext.com/careers/.